{"product_id":"genvoy-ilm-t-cell-kits-for-mrna-1000701","title":"GenVoy-ILM™ T cell kits for mRNA","description":"\u003cp\u003eGenVoy-ILM™ T cell Kit for mRNA is a lipid nanoparticle (LNP) reagent mix optimized for the delivery of mRNA or CRISPR Cas9 mRNA with gRNA into human primary T cells using LNPs prepared on the NanoAssemblr™ Spark™ and Ignite™ systems.\u003c\/p\u003e\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eGenVoy-ILM™ T cell Kits for mRNA offers the following benefits:\u003c\/p\u003e\n\n\u003cul\u003e\n\t\u003cli class=\"-font--body\"\u003e\n\u003cstrong\u003eHighly efficient knockout and expression:\u003c\/strong\u003e The mRNA or mRNA\/sgRNA can be delivered into activated human primary T cells consistently with high gene knockout efficiency.\u003c\/li\u003e\n\t\u003cli class=\"-font--body\"\u003e\n\u003cstrong\u003eHigh cell viability:\u003c\/strong\u003e Maintain high T cell viability, even after sequential genetic manipulation.\u003c\/li\u003e\n\t\u003cli class=\"-font--body\"\u003e\n\u003cstrong\u003eScalable:\u003c\/strong\u003e Scale your cell therapy research on the NanoAssemblr™ platform from discovery to preclinical.\u003c\/li\u003e\n\t\u003cli class=\"-font--body\"\u003e\n\u003cstrong\u003eValidated with T cell manufacturing workflow:\u003c\/strong\u003e Optimized and validated for downstream T cell culture workflow.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe kits enable researchers to establish a clinically relevant and scalable method for \u003cem\u003eex vivo\u003c\/em\u003e gene delivery and gene editing to advance the development of T cell therapies. These kits can be used at various stages of cell therapy research and development from discovery to preclinical across the NanoAssemblr™ platforms.\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eGreater ratio of engineered T cells compared to electroporation (EP)\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eUsing the GenVoy-ILM™ T cell Kit for mRNA to deliver mRNA into activated human primary T cells results in an increased number of engineered T cells. This method demonstrates a more effective gene delivery method compared to EP.\u003c\/p\u003e\n\n\u003cp\u003e\u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/jZUKP9BQSEulL99fjFiXWA-large\" style=\"max-width: 1250px;\"\u003e\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eTransfection efficiency was measured by protein expression via flow cytometry at 24 and 48 hours post-treatment. EP was performed by following the manufacturer’s protocol, and LNP treatment was performed following the GenVoy-ILM™ T cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as control. **p\u0026lt;0.01, ****p\u0026lt;0.0001 by one-way ANOVA.\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eUniform cellular protein expression\u003c\/p\u003e\n\n\u003cp\u003eEngineering human primary T cells using the GenVoy-ILM™ T cell Kit for mRNA results in highly uniform protein expression across the treated cell population.\u003c\/p\u003e\n\n\u003cp\u003e\u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/1CPxSKqlTTSsuN91NrkbTg-original-png\" style=\"max-width: 1250px;\"\u003e\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eRepresentative mean fluorescence intensity (MFI) plots of cell surface protein expression were generated using flow cytometry at 24 and 48 hours post-treatment. EP was performed by following the manufacturer’s protocol. Untreated cells (UT) were used as controls.\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eHighly viable T cells\u003c\/p\u003e\n\n\u003cp\u003eActivated human primary T cells remain highly viable after \u003cem\u003eex vivo\u003c\/em\u003e gene delivery using the GenVoy-ILM™ T cell Kit for mRNA.\u003c\/p\u003e\n\n\u003cp\u003e\u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/mCKHQJyVQlWPxdADf2_KoQ-original-png?v=343d1041\" style=\"max-width: 1250px;\"\u003e\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eCell viability was measured via flow cytometry at 24 and 48 hours post-treatment. EP was performed by following the manufacturer’s protocol, and LNP treatment was performed following the GenVoy-ILM™ T cell Kit for mRNA on Spark™ protocol. Untreated cells (UT) were used as controls. ****p\u0026lt;0.0001 by one-way ANOVA.\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eMulti-step engineering of T cells for off-the-shelf cell therapy\u003c\/p\u003e\n\n\u003cp\u003eAchieve highly efficient genome editing knockouts in combination with high levels of CD19 CAR expression. This allows for the engineering of functional and viable “universal” CAR T cells that effectively kill CD19+ tumor cells.\u003c\/p\u003e\n\n\u003cp\u003e\u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/V48HbQ3hQkqHupJqZpOZEA-original-png?v=60dbe059\" style=\"max-width: 1150px;\"\u003e\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eA) Schematic illustration of experiment. mRNA-LNPs containing sgRNA + Cas9 mRNA were added to primary T cells. Cells expanded prior to treatment with CD19 CAR mRNA-LNPs. At 24 hours post CAR mRNA-LNP treatment, CD19+ T cell killing assay was conducted for 16 hours. B) TCR knockout efficiency was assessed. Starting sample was TCR negative selected to further purify the TCR- population. C) Left: Percent CD19 CAR expression 24 hours after treatment with CAR mRNA-LNPs at 3.2 μg RNA\/million cells, when population is TCR+, or TCR−. Right: Corresponding cell viabilities, normalized to the untreated population. D) Functional killing of CD19+ B cells (SUP-B15) by either UT, TCR+\/CAR+, or gene-edited TCR−\/CAR+ T cells at the indicated effector to target ratios (E:T). For all, a dose of 3.2 μg RNA\/million cells was applied. Error bars represent standard deviation. Statistical significance was evaluated using t-tests or one-way ANOVA among the shown groups (2).\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eScale up from discovery to preclinical\u003c\/p\u003e\n\n\u003cp\u003eThe data demonstrates that the GenVoy-ILM™ T cell Kits and the scalable NanoAssemblr™ platform enable robust and equivalent performance on both the Spark™ and Ignite™ instruments enabling scale up from discovery to preclinical.\u003c\/p\u003e\n\n\u003cp\u003e\u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/_6AxVcEQSKKQptBRUsXjCw-original-png?v=fe1a20aa\" style=\"max-width: 1250px;\"\u003e \u003cimg alt=\"\" class=\"img-responsive center-block\" src=\"https:\/\/cdn.cytivalifesciences.com\/api\/public\/content\/812C6PHyQ7eq6Rr6GInWrw-original-png?v=04b8a698\" style=\"max-width: px;\"\u003e\u003c\/p\u003e\n\n\u003cp class=\"-font--minus-1\"\u003eA) GFP and B) CD19 CAR transfection efficiency 24 hours post mRNA-LNP addition. C) Levels of single target (T cell receptor, TCR) knockout, and D) Double target (TCR and CD52) knockout through sgRNA and Cas9 mRNA delivery. E) Functional killing of CD19+ B cells (SUP-B15) in a 16-hour co-culture experiment. For all: a dose of 3.2 μg RNA\/million cells was applied to human primary T cells. RNA-LNPs were prepared according to the GenVoy-ILM™ T cell Kit for mRNA on Spark™ or Ignite™ user guides. Average gene expression and gene knockout was detected by flow cytometry showing at minimum n=8 independent RNA-LNP preparations and n=2 donors. Functional killing performance was detected by flow cytometry showing n=2 independent RNA-LNP preparations and n=2 donors. Error bars represent standard deviation with statistical significance evaluated using t-tests among selected groups (2).\u003c\/p\u003e\n\n\u003cp class=\"-font--plus-1 -padding--title-md\"\u003eKit components\u003c\/p\u003e\n\n\u003cdiv class=\"table-responsive\"\u003e\n\u003ctable class=\"table table-bordered\"\u003e\n\t\u003cthead\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003cth class=\"-font--body\"\u003e \u003c\/th\u003e\n\t\t\t\u003cth class=\"-font--body\"\u003eGenVoy-ILM™ T cell Kit for mRNA, Spark™, (Part no. 1000700)\u003c\/th\u003e\n\t\t\t\u003cth class=\"-font--body\"\u003eGenVoy-ILM™ T cell Kit for mRNA w\/ 5 Spark™ cartridge, (Part no. 1000683)\u003c\/th\u003e\n\t\t\t\u003cth class=\"-font--body\"\u003eGenVoy-ILM™ T cell Kit for mRNA, Ignite™, 3 mL, (Part no. 1001144)\u003c\/th\u003e\n\t\t\t\u003cth class=\"-font--body\"\u003eGenVoy-ILM™ T cell Kit for mRNA, Ignite™, 6 mL, (Part no. 1001161)\u003c\/th\u003e\n\t\t\u003c\/tr\u003e\n\t\u003c\/thead\u003e\n\t\u003ctbody\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eLipid mix\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e90 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e90 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e3 mL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e6 mL\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eFormulation buffer (10X)\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e30 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e30 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e2 mL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e4 mL\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eDilution buffer (10X)\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e900 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e900 µL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e40 mL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e80 mL\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eCryopreservation buffer (2X)\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e-\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e-\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e3 mL\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e6 mL\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eApolipoprotein-E (ApoE)\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e50 µg\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e50 µg\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e500 µg\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e500 µg x 2\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\t\u003ctr\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003eSpark Cartridges\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e-\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e5\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e-\u003c\/td\u003e\n\t\t\t\u003ctd class=\"-font--body\"\u003e-\u003c\/td\u003e\n\t\t\u003c\/tr\u003e\n\t\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch2\u003eDocuments\u003c\/h2\u003e\n\u003cul\u003e\u003cli\u003e\u003ca href=\"https:\/\/d3.cytivalifesciences.com\/prod\/IFU\/01001343.pdf\"\u003eInstructions for use (PDF)\u003c\/a\u003e\u003c\/li\u003e\u003c\/ul\u003e","brand":"Cytiva","offers":[{"title":"Ignite (1001144)","offer_id":45982115627087,"sku":"1001144","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Ignite (1001161)","offer_id":45982115659855,"sku":"1001161","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Spark (1000701)","offer_id":45982115692623,"sku":"1000701","price":0.0,"currency_code":"ILS","in_stock":true},{"title":"Spark (29874064)","offer_id":45982115725391,"sku":"29874064","price":0.0,"currency_code":"ILS","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0712\/0748\/5519\/files\/W-GiOF0YT7G2-ss2TM1BvQ-original-png_b3850b8e-04d7-4599-9cd8-cfb896f2b679.png?v=1785958486","url":"https:\/\/www.danyel.co.il\/products\/genvoy-ilm-t-cell-kits-for-mrna-1000701","provider":"danyel biotech","version":"1.0","type":"link"}